MorphoSys

DE0006632003

MorphoSys AG is a biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany and has a wholly owned subsidiary, MorphoSys US Inc., in Boston MA in the US, where it is building a commercial organization. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company claims to have more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer. MorphoSys AG is listed on the Frankfurt Stock Exchange and on the US Nasdaq stock exchange.

MorphoSys was a target of short sellers in the past, but no short positions have been reported for 755 days.